When was Lygos founded?

Lygos was founded in 2011 and raised its 1st funding round within a year of its incorporation.

Where is Lygos located?

Lygos is headquartered in Berkeley, United States.

How many employees does Lygos have?

As of Sep 30, 2026, the latest employee count at Lygos is 25.

Is Lygos a funded company?

Lygos is a funded company, having raised a total of $51.8M across 30 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on 2011.

When was the latest funding round of Lygos?

Lygos' latest funding was a $***** Grant (prize money) round on Jul 25, 2025, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $1.87B in funding in 2026 to date.

Where does Lygos rank among its competitors?

Lygos ranks 71st amongst 2233 active competitors, of which 493 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Fermbox, which secured an undisclosed amount in Jul, 2026.

Who are the top competitors of Lygos?

Lygos' top competitors include LanzaTech, Antheia and Fermbox. Among them, Fermbox secured the most recent funding round in July, 2026.

Lygos - 2026 Company Profile, Team, Funding & Competitors

Company Details

Manufacturer of green acids from microbes. It employs synthetic biology techniques to generate microbial catalysts to convert agricultural feedstocks into fine and commodity chemicals. Its high throughput screening and strain construction facilitate the optimization of pathways to convert the renewable feedstock to high-value chemicals. Its product portfolio includes malonic, lactic, isobutyric, aspartic, glyceric, and glycolic acids.

Website: www.lygos.com/
Social

Key Metrics

Founded Year

2011

Location

Berkeley, United States

Stage

Series B

Total Funding

$51.8M in 30 rounds

Latest Funding Round

Grant (prize money), Jul 25, 2025, $*****

Investors

IA Ventures & 22 more

Ranked

71^st among 2233 active competitors

Employee Count

25 as on Sep 30, 2026

Investment & Acquisitions

Librede

Similar Companies

Antheia & 2749 more

View Lygos' full profile

Lygos is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Lygos, Inc. CIN: 27-3280691 , United States, Active		-	63 (As on Dec 31, 2023)	-

Lygos has raised a total funding of $51.8M over 30 rounds. Its first funding round was on 2011. Its latest funding round was a Grant (prize money) round on Jul 25, 2025 for $*****. 1 investor participated in its latest round. Lygos has 23 institutional investors.

Here is the list of recent funding rounds of Lygos:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 25, 2025	2470420	Grant (prize money)	2878009	9318102	4196620	8910599
Apr 04, 2025	9748376	Grant (prize money)	8341568	9395109	5223825	National Science Foundation
Feb 09, 2021	3699706	Series B	7532928	8847460	Flexible Solutions & 1 more	6258416

Access funding benchmarks and valuations. Sign up today!

View details of Lygos's funding rounds and investors

Lygos' Board of Directors

Lygos's board has 8 active members. Jay Keasling, Brad Gillespie, Jeffrey Dietrich, Jeffrey L. Fortman, Eric Steen, Leonard Katz, Jay D. Keasling and Jeffrey A. Dietrich are independent board members.

Here is the list of Lygos' board of directors:

Name	Type	Representing	Status	Duration
Jay Keasling	Independent board member	-	Current	9y 10m
rdanhaj	Independent board member	-	Current	4y 3m
ljvdotm	Independent board member	-	Current	5y 7m
urla{yj	Independent board member	-	Current	5y 5m
ltkbojn	Independent board member	-	Current	6y 5m
harepnw	Independent board member	-	Current	2y 9m
boebmfj	Independent board member	-	Current	3y 2m
vxhxnwk	Independent board member	-	Current	1y 1m

Lygos' employee count trend

Lygos has 25 employees as of Sep 26. Here is Lygos's employee count trend over the years:

Uncover Lygos' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lygos include LanzaTech, Antheia and Fermbox. Here is the list of Top 10 competitors of Lygos, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	LanzaTech 2005, Skokie (United States), Public	Developer of technology converting carbon-rich gases into fuels and chemicals	$869M	Malaysian Life Sciences Capital Fund, BASF ... & 28 others	69/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	68/100
3rd	Fermbox 2022, Bengaluru (India), Series A	Company focused on developing alternative animal products through microbial precision fermentation	$14.5M	3one4 Capital, Speciale Invest & 18 others	67/100
4th	Synthego 2012, Redwood City (United States), Acquired	Manufacturer of custom CRISPR gene editors and molecular biology reagents	$460M	8VC, Perceptive Advisors & 31 others	67/100
5th	Axol Bioscience 2013, Cambridge (United Kingdom), Series A	Provider of human cells, reagents, and reprogramming services	$13.3M	Calculus Capital, Scottish Enterprise & 13 others	65/100
6th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
7th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 15 others	65/100
8th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
9th	Avalyn Pharma 2011, Seattle (United States), Public	Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis	$389M	Perceptive Advisors, Norwest & 22 others	64/100
10th	enGene 1999, Saint laurent (Canada), Public	Developer of oral non-viral gene therapy platform	$54M	Hercules Capital, Lumira Ventures & 15 others	63/100
71st	Lygos 2011, Berkeley (United States), Series B	Manufacturer of green acids from microbes	$51.8M	Flying Cow Ventures, 10x Group & 21 others	54/100